Vis enkel innførsel

dc.contributor.authorAaseth, Jan
dc.contributor.authorNurchi, Valeria Marina
dc.contributor.authorAndersen, Ole
dc.date.accessioned2020-06-04T08:13:47Z
dc.date.available2020-06-04T08:13:47Z
dc.date.created2020-01-19T12:31:19Z
dc.date.issued2019
dc.identifier.citationBiomolecules. 2019, 9:856 (12), 1-10.en_US
dc.identifier.issn2218-273X
dc.identifier.urihttps://hdl.handle.net/11250/2656479
dc.description.abstractFollow-up studies after the Chernobyl and Fukushima accidents have shown that 137Cs and 131I made up the major amount of harmful contaminants in the atmospheric dispersion and fallout. Other potential sources for such radionuclide exposure may be terrorist attacks, e.g., via contamination of drinking water reservoirs. A primary purpose of radionuclide mobilization is to minimize the radiation dose. Rapid initiation of treatment of poisoned patients is imperative after a contaminating event. Internal contamination with radioactive material can expose patients to prolonged radiation, thus leading to short- and long-term clinical consequences. After the patient’s emergency conditions are addressed, the treating physicians and assisting experts should assess the amount of radioactive material that has been internalized. This evaluation should include estimation of the radiation dose that is delivered and the specific radionuclides inside the body. These complex assessments warrant the reliance on a multidisciplinary approach that incorporates regional experts in radiation medicine and emergencies. Regional hospitals should have elaborated strategies for the handling of radiation emergencies. If radioactive cesium is a significant pollutant, Prussian blue is the approved antidote for internal detoxification. Upon risks of radioiodine exposure, prophylactic or immediate treatment with potassium iodide tablets is recommended. Chelators developed from calcium salts have been studied for gastrointestinal trapping and enhanced mobilization after strontium exposure.en_US
dc.description.sponsorshipThis research was funded by Regione Autonoma della Sardegna for the financial support grant number RASSR79857 “Metallo-farmaci innovativi: biotrasformazione e target biologici. Un approccio integrato”.en_US
dc.language.isoengen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectcesium;en_US
dc.subjectradioactive terrorism;en_US
dc.subjectradiation dosage;en_US
dc.subjectchelation therapy;en_US
dc.subjectiodine;en_US
dc.subjectstrontium;en_US
dc.subjectPrussian blueen_US
dc.titleMedical therapy of patients contaminated with radioactive cesium or iodineen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.source.pagenumber1-10en_US
dc.source.volume9:856en_US
dc.source.journalBiomoleculesen_US
dc.source.issue12en_US
dc.identifier.doi10.3390/biom9120856
dc.identifier.cristin1776706
cristin.unitcode1991,5,6,0
cristin.unitnameAvd Indremedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal